



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 48/00, C12N 15/86	A1	(11) International Publication Number: WO 98/22143 (43) International Publication Date: 28 May 1998 (28.05.98)
(21) International Application Number: PCT/US97/21169 (22) International Filing Date: 19 November 1997 (19.11.97) (30) Priority Data: 60/031,323 19 November 1996 (19.11.96) US 60/037,081 4 February 1997 (04.02.97) US (71) Applicant: UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION [US/US]; 701 20th Street South, Birmingham, AL 35294-0011 (US). (72) Inventor: CURIEL, David, T.; 824 Linwood Drive, Birmingham, AL 35222 (US). (74) Agent: ADLER, Benjamin, A.; McGregor & Adler, 8011 Candle Lane, Houston, TX 77071 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: CHIMERIC RETROVIRUS/ADENOVIRUS SYSTEM (57) Abstract The present invention provides a chimeric viral vector system having a highly efficient in vivo gene delivery to cells after vascular administration and an integrative capacity of heterologous gene sequences for stable genetic modification of cells after transduction. In this chimeric vector, an adenoviral vector is employed to deliver retroviral functions to a cell for local, <i>in situ</i> production of retroviral particles inside the cell by the construction of replication-defective adenoviral vectors which contain either retroviral "packaging" functions (retroviral genes <i>gag</i> , <i>pol</i> , <i>env</i>) and retroviral "vector" functions (retroviral LTR sequences flanking the "therapeutic" gene).		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

CHIMERIC RETROVIRUS/ADENOVIRUS SYSTEM

10

BACKGROUND OF THE INVENTION

Cross-reference to Related Application

15 This application claims the benefit of provisional applications 60/031,323, filed November 19, 1996 and 60/037,081, filed February 4, 1997.

Field of the Invention

20 The present invention relates generally to the fields of molecular biology of vectors and gene therapy. More specifically, the present invention relates to a chimeric adenoviral vector system and methods for its use.

Description of the Related Art

25 A number of gene therapy strategies for diseases of the heart, lung, and blood are based upon stable genetic modification of relevant parenchymal cells. In many contexts, this can be only achieved by direct *in vivo* gene delivery whereby
30 stable transduction is achieved *in situ*. To this end, a variety of viral vectors have been developed to exploit their integrative capacity as a means to achieve stable genetic transduction. Vectors of this type include recombinant retroviruses and adeno-associated viruses (AAV) and have been employed in *ex vivo* gene
35 transfer schemes to achieve stable genetic modification of target cells.

Despite the utility of retroviral and AAV vectors in these *ex vivo* contexts, employment of these vectors for direct *in vivo* gene delivery has been problematic. In this regard, issues of effective titer and *in vivo* stability have limited the utility of these vectors for the many schemes whereby direct *in situ* transduction of a parenchyma is required. On the other hand, recombinant adenoviral vectors can be prepared to high titer, and possess *in vivo* stability, both factors which have allowed their employment for direct *in vivo* gene delivery to differentiated target cells. The limitation of adenoviral vectors, however, is that the derived heterologous gene expression is only transient. This is based, in part, upon the fact that adenoviral vector transduced cells are immunologically eradicated by the host. In addition, the parent adenovirus lacks the capacity to integrate its genome in the host chromosome.

The prior art is deficient in the lack of effective vector system which allows stable genetic modification of cells after direct *in vivo* vector administration. The present invention fulfills this longstanding need and desire in the art.

SUMMARY OF THE INVENTION

Retroviral integrative functions can be exploited, in the context of adenoviral vectors, to derive a system which can achieve efficient, stable transduction of target cells *in vivo*. The present invention shows that retroviral vector packaging and retroviral vector functions can operate in the context of adenoviral vector constructs, with the successful derivation of integrative progeny retroviral vectors. In this schema, target cells are induced to function as transient retroviral "producer cells" by a combination of adenoviral vector-mediated delivery of retroviral vector sequences in concert with adenoviral vector expression of retroviral packaging function. In the *in vivo* context, high efficiency delivery of retroviral packaging and vector functions could be achieved at parenchymal sites via adenoviral vectors to achieve this *in situ*. Thus, locally elaborated retroviral vectors could secondarily infect neighbor cells to achieve stable genetic transduction. Thus, a "chimeric" vector system has been

developed which exploits favorable characteristics of each component vector.

It is an object of the present invention to develop adenoviral vectors containing retroviral integrative functions and to optimize their employment *in vitro*, for achievement of stable transduction of target cells.

It is another object of the present invention to employ these chimeric vectors to achieve stable *in vivo* genetic modification of parenchymal cells relevant to diseases of the heart, lung, and blood.

The development of adenoviral vectors with integrative capacity would allow these vectors to achieve stable integration of transgenes *in vivo*. This strategy would thus exploit the favorable characteristics of each component vector system to allow stable gene expression at parenchymal target sites significantly improving the possibilities of achieving effective genetic correction in the context of gene therapy applications for diseases of the heart, lung, and blood.

In one embodiment of the present invention, there is provided a chimeric adenoviral/retroviral vector, comprising: at least one adenoviral vector containing retroviral sequences.

In one embodiment of the present invention, there is provided method of stably transducing target cells, comprising the step of administering the chimeric adenoviral/retroviral vector of the present invention to an individual in need of such treatment.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings

form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

5

Figure 1 shows the schema of local generation of retroviral vector at a target organ site. Adenoviral vectors encoding retroviral vector and packaging functions accomplish *in vivo* gene transfer to target parenchymal cells at high efficiency, rendering them transient retroviral producer cells. The locally elaborated retroviral particles can thus directly infect neighbor cells.

Figure 2 shows (**Figure 2A**) Maps of adenoviral shuttle plasmids containing retroviral packaging functions, and (**Figure 2B**) Maps of adenoviral shuttle plasmids containing retroviral vector functions.

Figure 3 shows the structural validation of adenoviral vector via molecular analysis.

Figure 4 shows maps of constructed adenoviral vectors encoding HGF and KGF for induction of target cell proliferation *in vivo*.

Figure 5 shows the persistent gene expression achieved via the adenoviral/retroviral chimeric vector system. Target cells were infected with AdLNCMVGFP plus AdCMVAmpg or AdLNCMVGFP alone and then analyzed for stable genetic transduction. GFP expression in W162 cells was analyzed by fluorescent microscopy at indicated time points after adenoviral vector infection.

Figure 6 shows the persistent gene expression. Target cells were infected with AdLNCMVGFP plus AdCMVAmpg or AdLNCMVGFP alone and analyzed for stable genetic transduction. **Figure 6A** shows the FACS analysis of GFP expression in W162 cells at indicated times post-infection. **Figure 6B** shows an analysis of genomic DNA extracted from W162 cells harvested at day 30 post-infection. HMW DNA of cells was digested with *MunI*, and probed with a retrovirus vector-proviral segment. The DNA in lane 1 was extracted from cells infected with AdLNCMVGFP and AdCMVAmpg; lane 2 DNA was

extracted from cells infected with AdLNCMVGFP alone; and lane 3 is a control containing AdLNCMVGFP genomic DNA digested with *MunI*.

5 **Figure 7** shows the derivation of transducing retroviral particles via the adenoviral/retroviral chimeric vector. Indicated cells were treated with AdLNCMVGFP only or AdLNCMVGFP plus AdCMVAmpg and supernatants analyzed for retroviral vector particles by titering on NIH-3T3 cells. Supernatant treated cells were analyzed at day 20 by fluorescent
10 microscopy.

Figure 8 shows *in vivo* gene transfer via the adenoviral/retroviral chimeric vector. SKOV3_{ip1} cells were implanted intraperitoneally. **Figure 6A** shows a hematoxylin stained intraperitoneal tumor nodule. Animals challenged with
15 either **Figure 6B** AdLNCMVGFP alone or (**Figure 6C**) AdLNCMVGFP and AdCMVAmpg were analyzed by fluorescent microscopy for expression of GFP at day sixteen.

Figure 9 shows *in vivo* gene transfer via the adenoviral/retroviral chimeric vector. SKOV3_{ip1} cells were
20 infected with either AdLNCMVGFP (**Figure 9B**) or AdLNCMVGFP plus AdCMVAmpg (**Figure 9C**), mixed with virgin tumor cells and implanted subcutaneously in athymic nude mice. At day 20, tumors were harvested and analyzed by fluorescent microscopy. (**Figure 9A**) Hematoxylin-stained section taken from a two
25 virus, subcutaneous nodule. SKOV3_{ip1} cells were implanted intraperitoneally and animals challenged with either AdLNCMVGFP alone (**Figure 9E**) or AdLNCMVGFP plus AdCMVAmpg (**Figure 9F**). Analysis was by fluorescent microscopy for expression of the GFP reported at day sixteen.
30 (**Figure 9D**) A hematoxylin stained intraperitoneal tumor nodule.

DETAILED DESCRIPTION OF THE INVENTION

35 The present invention is directed to a vector system that provides both highly efficient *in vivo* gene delivery to cells after vascular administration and has an integrative capacity of heterologous gene sequences to accomplish stable genetic

modification of cells after transduction. In the chimeric vector of the present invention, an adenoviral vector is employed to deliver retroviral functions to a cell for local, *in situ* production of retroviral particles inside the cell. This is accomplished by the construction of replication-defective adenoviral vectors which contain either retroviral "packaging" functions (retroviral genes *gag*, *pol*, *env*) and retroviral "vector" functions (retroviral LTR sequences flanking the "therapeutic" gene). These adenoviral vectors are capable of co-delivering gene products with high efficiency to cells based on the adenoviral vector's recognized capacity to achieve efficient *in vivo* transduction after vascular vector administration.

Cells, such as hepatocytes transduced with these adenoviral vectors are then rendered into transient retroviral vector "producer cells". These cells transiently express retroviral vector functions. The cells can thus elaborate retroviral particles containing the therapeutic gene. By virtue of the "local", *in situ* production of retroviral particles, efficient transduction of neighboring cells is achieved with the elaborated retroviral particles. This method thus overcomes the obligate loss of retroviral vectors which occurs with "distant" vascular administrations. In addition, transduced "neighbor" cells are stably modified by virtue of the fact that retroviral vectors accomplish the transduction event. This event thus overcomes the principal limitation of adenoviral vectors by allowing for an integrative transduction event.

One unique attribute of this chimeric viral vector system is thus the exploitation of adenoviral vector delivery elements to achieve effective *in situ* retroviral transduction. This concept can be extended to deliver other genes which could render cells further susceptible to retroviral vectors produced "locally". In this regard, retroviral infection is enhanced by proliferation of target cells.

The present invention is directed to a chimeric adenoviral/retroviral vector, comprising: at least one adenoviral vector containing retroviral sequences. Preferably, the chimeric adenoviral/retroviral vector comprises: (a) a replication-deficient adenoviral vector containing retroviral vector functions; and (b) at

least one replication-deficient adenoviral vector containing retroviral packaging functions. Preferably, the retroviral vector functions comprise a heterologous gene and such gene is flanked by retroviral long terminal repeats. Generally, the retroviral packaging functions are selected from the group consisting of *gag*, *pol* and *env*, or combinations thereof. A person having ordinary skill in this art would recognize that one may substitute alternate *env* genes to more specifically target a cell. For example, one may use the *env* gene is a vesicular stomatitis virus G-glycoprotein as described in detail below. Preferably, the heterologous gene is selected from the group consisting of a gene encoding a therapeutic protein, a selectable marker and a reporter gene. A person having ordinary skill in this art would recognize that one may exploit a wide variety of genes encoding proteins, e.g., therapeutic proteins, either to replace such a protein or to augment or inhibit a specific biochemical activity.

The present invention is also directed to a method of stably transducing target cells, comprising the step of administering the chimeric adenoviral/retroviral vector of the present invention to an individual in need of such treatment. Preferably, the chimeric adenoviral/retroviral vector comprises: (a) a replication-deficient adenoviral vector containing retroviral vector functions; and (b) at least one replication-deficient adenoviral vector containing retroviral packaging functions. Preferably, the retroviral vector functions comprise a heterologous gene and such gene is flanked by retroviral long terminal repeats. Generally, the retroviral packaging functions are selected from the group consisting of *gag*, *pol* and *env*, or combinations thereof. A person having ordinary skill in this art would recognize that one may substitute alternate *env* genes to more specifically target a cell. For example, one may use the *env* gene is a vesicular stomatitis virus G-glycoprotein as described in detail below. Preferably, the heterologous gene is selected from the group consisting of a gene encoding a therapeutic protein, a selectable marker and a reporter gene. A person having ordinary skill in this art would recognize that one may exploit a wide variety of genes encoding proteins, e.g., therapeutic proteins, either to replace such a protein or to augment or inhibit a specific

biochemical activity. Using the methods described below, one may administer a replication-deficient adenoviral vector containing retroviral vector functions; and said replication-deficient adenoviral vector containing retroviral packaging functions are co-
5 transduced into a host cell, wherein expression of the genes encoded by said adenovirus shuttle vector results in the production of retrovirus particles containing said therapeutic gene, wherein said retrovirus particles infect neighboring cells, wherein said retrovirus particles stably integrate said therapeutic gene
10 into said host cells' genomic DNA.

A person having ordinary skill in this art would recognize that one may specifically target the chimeric adenoviral/retroviral vector of the present invention by various manipulations. For example, one may genetically modify the fiber
15 or knob component of the adenoviral vector, e.g., by incorporating a ligand that specifically recognizes a cell surface receptor. Alternatively, one may target the adenovirus immunologically using single chain antibodies or Fab fragments as is known in the art.

20 The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

EXAMPLE 1

25 Employment of adenoviral vectors containing retroviral integrative functions for stable transduction of target cells

To achieve long term heterologous gene expression consequent to efficient *in vivo* gene delivery, retroviral integrative features can be coupled to adenoviral vector systems.
30 This is accomplished by employing replicative-deficient adenoviral vectors to deliver both retroviral packaging functions and retroviral vector sequences to target cells *in situ*. The co-transduced cells then function as retroviral producer cells. In this schema, the locally elaborated retroviral particles stably transduce
35 "neighbor cells" within the surrounding parenchyma, thus achieving efficient integration of transgene sequences of relevant target organs for gene therapy purposes. The ability of adenoviral vectors to deliver relevant retroviral functions for the efficient

induction of target cells to function as retroviral producer cells is shown.

EXAMPLE 2

5 Plasmid vectors and cells

To generate the adenoviral/retroviral chimeras, individual elements of the retroviral genome components were first incorporated into two distinct adenoviral shuttle vectors designated pCAAmpg and pΔE1LNCX. Shuttle vectors were also
10 generated containing reporter genes, resulting in pΔE1LNCMVGFp which encodes the green fluorescent protein (GFP) cDNA and pΔE1LNCMVLacZ encoding the *Escherichia coli* β-galactosidase (LacZ) gene.

For pCAAmpg, the DNA fragments encoding the
15 retroviral *gag/pol* and amphotropic *env* genes were isolated from pPAM3 (provided by Dr. Dusty A. Miller, Fred Hutchinson Cancer Research Center, Seattle, WA) in a two-step PCR/restriction digest procedure as follows: A 133 bp PCR fragment including the *gag/pol* transcription initiation site was amplified from pPAM3
20 using an upstream primer, 5'-gggaagccttatgggccagactgtaccac (SEQ ID No. 1), containing a *Hind*III site, and a downstream primer 5'-caaggcttcccaggtcacgatgtagg (SEQ ID No.2), encompassing an internal *Pst*I site. This fragment was digested with *Hind*III and *Pst*I prior to cloning. The remaining 7.0 kb *gag/pol/env* segment
25 was obtained from pPAM3 with *Pst*I-*Hpa*I digestion. The two retroviral fragments were triple ligated into the adenoviral shuttle vector pCA13 (Microbix Biosystems Inc., Ontario, Canada) at *Hind*III-*Eco*RV sites to obtain the pCAAmpg vector (13.9 kb).

To construct an adenoviral shuttle vector containing
30 retroviral integration sequences, neomycin resistance cDNA, a CMV promoter and multiple cloning sites, the retroviral vector pLNCX (Dr. A. Dusty Miller) was partially digested with *Eco*RI and *Hind*III to obtain a 3.6 kb fragment. This fragment was subsequently subcloned into a modified version of pZero-1™
35 (Invitrogen, La Jolla, CA, USA) in which a *Cla*I site was introduced by silent mutation between the *Eco*RV and *Not*I sites. The resultant construct was labeled as pEH3.6. The remaining retroviral vector sequence was obtained by *Apa*I and *Hind*III

digestion and the resulting fragment was subcloned into pZero-1™ at *Hind*III and *Eco*RV sites to be pHA0.9. The 3.6 kb *Cla*I-*Hind*III fragment from pEH3.6 and the 1.0 kb *Hind*III-*Xho*I fragment from pHA0.9 were triple ligated in pΔE1SP1A (Microbix, Biosystems Inc.) at *Cla*I and *Xho*I sites to create pΔE1LNCX. The 0.9kb GFP cDNA segment was excised from pEGFP-NI (Clontech Inc., Palo Alto, CA, USA) by *Hind*III-*Hpa*I digestion and subcloned into pΔE1LNCX at *Hind*III and *Hpa*I sites. A similar scheme was used to construct pΔE1LNCMVlacZ from pΔE1LNCX. The shuttle vectors pCAmpg, pΔE1LNCX, pΔE1LNCMVGFP, pΔE1LNCMVlacZ were confirmed by restriction enzyme analysis and partially sequenced using USB 70770 Sequencing kit (Amersham, Cleveland, Ohio, USA).

NIH-3T3 fibroblasts, 293 cells, EJ bladder carcinoma cells (ATCC, Rockville, Maryland), W162 (Gary Ketner, Princeton University) and SKOV3_{ip1} cells (Dr. Janet Price, M.D. Anderson Cancer Center, Houston, TX) were maintained in complete medium composed of Dulbecco's Modified Eagle's Medium/Ham's F12 (DMEM/F12, Mediatech, Inc.; Washington, D.C) supplemented with 10% fetal bovine serum (FBS, Hyclone; Logan, UT), 2 mM glutamine (Mediatech) and penicillin/streptomycin (Cellgro Mediatech). All cells were maintained at 37°C in 5% CO₂.

EXAMPLE 3

2.5 Generation of recombinant adenoviral vectors

E1A/B and E3 deleted replication-deficient recombinant adenoviral vectors were generated by *in vitro* homologous recombination method. In these studies, the pCAmpg, pΔE1LNCMVlacZ or pΔE1LNCMVGFP shuttle plasmids were co-transfected with pBGH11 (Microbix Biosystems Inc.) into 293 cells to generate AdCMVampg, AdLNCMVlacZ or AdLNCMVGFP, respectively. Each adenovirus was passed through three rounds of plaque purification and subsequently confirmed by PCR analysis and restriction enzyme mapping. Recombinant adenoviruses were propagated on the permissive 293 cell line, purified twice by CsCl gradient centrifugation, and plaque titered using standard methods.

EXAMPLE 4

Retroviral particle generation and detection

Cells were plated into 100-mm tissue culture plates
5 (10⁶ cells/plate) in complete medium containing 10% FBS and
incubated overnight at 37°C in 5% CO₂. For initial testing of
plasmid constructs, 293 cells were transfected by calcium
phosphate precipitation with either pΔE1LNCMVlacZ plus
pCAampg or with pLNCLX and pPAM3. The following day, the
10 cells were fed with fresh complete medium. At 48 h post-
transfection, the supernatant was harvested and used to
determine retroviral titer on NIH-3T3 cells. For adenoviral
infection, the culture medium was aspirated and replaced with
DMEM/F12 plus 2% FBS containing either AdCMVampg plus
15 AdLNCMVGFP, or AdLNCMVGFP alone, at a ratio of 50 plaque-
forming units (pfu)/cell for each group. After 3 hours of
incubation, the medium was aspirated and the cells were rinsed
several times with PBS and fed with complete medium.
Retrovirus production was determined either directly by titering
20 the supernatant 48 h post-infection, or indirectly by monitoring
neighbor cells for retroviral infection. Long term cultures for
stable integration were passed at 8 day intervals. Retroviral titer
was carried out on NIH-3T3 cells. For this analysis, culture
supernatant from retroviral producer cells was harvested, filtered
25 (0.45 μm), and added to recipient cells at a 1:1 ratio to complete
medium plus 10 mg/ml polybrene. After 48 h, cells expressing
LacZ were visualized by X-gal histochemistry and titer was
determined by quantitation of the total blue cells/dish. Titer was
expressed as infectious virions/ml.

30

EXAMPLE 5

LacZ, GFP, and replication-competent retrovirus (RCR) assay

Cellular expression of LacZ was quantitatively analyzed
35 by staining with X-gal (5-bromo-4-chloro-3-indolyl-β-D-
galactoside). Cells were fixed with 0.25% glutaraldehyde/0.1 M
sodium phosphate for 15 minutes at room temperature followed
by washing with PBS and incubation overnight with X-gal staining

solution (0.2% X-gal/2 mM $MgCl_2$ /4 mM $K_4Fe(CN)_6$ /4 mM $K_4Fe(CN)_6 \cdot 3H_2O$ in PBS) at room temperature. X-gal positive (blue) cells were counted under light microscopy. Cellular GFP expression was quantitatively analyzed by FACS analysis, and by
5 visualization using fluorescent microscopy according to the manufacturer's protocol. (Clontech, CA, USA).

Feline S^+L^- (PG-4) cells were seeded in McCoy's 5A medium (BioWhittaker, Walkersville, MD) plus 15% FBS into 60-mm culture dishes approximately 24 h prior to inoculation. Five
10 replicate dishes were inoculated with 0.2 ml of sample dilutions; 1 and 10 focus forming units of amphotropic murine retrovirus 4070A as a positive control; and culture medium to serve as a negative control. After a 2 h adsorption period at $36 \pm 2^\circ C$ and fed with fresh medium, as necessary, for a period of 4-5 days until
15 foci of transformed cells were fully developed in the positive control dishes. The dishes were examined microscopically, and foci were counted. The assay was considered to be valid if no foci were observed in the negative control and the positive control dilutions had a mean titer within one log of the validated mean
20 titer of the positive control virus lot.

EXAMPLE 6

In vivo experiments and provirus integration

25 Female nude mice (4 to 6 weeks old) were injected i.p. with 1×10^7 SKOV3_{ip1} cells. Five days later, animals were i.p. injected with either AdCMVAmpg plus AdLNCMVGFp, or AdLNCMVGFp alone (1×10^9 pfu per mouse for each virus). Animals were sacrificed at 16 days post-adenovirus challenge.
30 Tumor nodules were harvested, fixed in 4% paraformaldehyde/PBS, sectioned and analyzed by fluorescence microscopy. For subcutaneous mixing studies, SKOV3_{ip1} cells were infected *ex vivo* at 50 pfu/per cell. Sixteen hours post-infection, the cells were washed twice with PBS, trypsinized, harvested,
35 counted, and mixed at a ratio of 1:4 with non-infected SKOV3_{ip1} cells. A total of 5×10^6 mixed cells were injected subcutaneously into the flanks of nude mice. Animals were sacrificed at day 20

post-injection. Tumor nodules were harvested for analysis by fluorescence microscopy.

To detect provirus integration, the high molecular weight fraction DNA was extracted from adenovirus treated cells. The DNA was *MunI* digested, resolved on a 0.8% agarose gel, and probed with a ³²P-labeled 1.4 kb fragment containing a retroviral vector sequence, which was obtained by PCR amplifying of AdLNCMVGFP from 4.8 kb to 6.2 kb. DNA labeling, membrane transfer, hybridization and washing procedures were performed according to the manufacturer's protocol (Amersham).

EXAMPLE 7

Elaboration of retroviral particles at parenchymal target sites to achieve stable transduction of neighbor cells

The present invention developed a "composite" vector system that combines the high efficiency *in vivo* gene delivery characteristics of recombinant adenoviral vectors with integrative capacities derived from retroviruses. This is accomplished by rendering adenoviral vector infected target cells into transient "retroviral producer cells" via adenoviral vector-mediated delivery of retroviral packaging functions and retroviral vector sequences. In this manner, the locally elaborated retroviral vectors can infect neighboring parenchymal cells via an integrative vector. The conceptual basis of this approach is depicted in Figure 1.

As a first step towards implementing this strategy, adenoviral vectors encoding retroviral vector sequences and retroviral packaging functions were derived. The derivation of these adenoviral vectors is based on methods whereby an adenoviral "shuttle" vector containing the transgene is co-transfected with the adenoviral packaging plasmid pJM17. The recombination of homologous regions within these plasmids results in a replication-deficient, *E1A/B*-deleted, adenoviral vector. As the adenoviral shuttle plasmids contain the intact expression cassettes destined for adenoviral vector incorporation, they provide the means to validate the functional utility of the transgene sequences *a priori*. Based on this concept, a series of

adenoviral shuttle vector plasmids containing relevant retroviral transgene sequences were derived. Thus, a series of plasmids were derived with retroviral functions *gag/poll/env*, *gag/pol*, or *env* cloned into the polylinker of the adenoviral shuttle vector
5 pCA13 (Figure 2).

These vectors would thus allow expression of the indicated retroviral packaging functions via a CMV intermediate/early enhancer-promoter. In addition, adenoviral shuttle plasmids encoding retroviral vector sequences were
10 derived. In this instance, the predicted adenoviral vector would function as a high efficiency delivery vehicle of the encoded transgene sequences. These retroviral vector sequences would then be packaged into retroviral particles, a process for which vector expression in target cells is not required. Thus, in these
15 instances retroviral vector sequences encoding either a *E. coli* β -galactosidase (LacZ) gene, in conjunction with a neomycin selectable marker, or the reporter gene green fluorescent protein (GFP) also in conjunction with a neomycin selectable marker, were cloned into polylinker of the "promoterless" adenoviral shuttle
20 vector (Figure 2).

These retrovirus vector gene constructs contain the indicated marker/reporter sequences flanked by intact retroviral long terminal repeats (LTRs). This was accomplished as these functions are the minimal sequences required *in cis* to allow
25 retroviral vector integration. These plasmids were all confirmed after construction by indirect analysis with restriction endonuclease digestion and direct analysis by dideoxy chain termination sequencing.

Functional analysis was used to confirm the operation
30 of retroviral packaging functions in the context of the adenoviral shuttle plasmid. For this study, the utility of the adenovirus shuttle plasmid containing retroviral packaging functions (pCAAmpg) was compared to the utility of a standard packaging plasmid, pPAM3, which contains the ecotropic retroviral genes
35 *gag/poll/env* under the control of Moloney Leukemia Virus (MLV) LTR. These plasmids were analyzed for their ability to rescue retroviral vector sequences from the control retroviral vector plasmid pLNCLZ, which contains a retroviral vector cassette

whereby the LacZ reporter gene is flanked by retroviral LTRs. After co-transfection of the plasmids into 293 cells, supernatants were harvested and used to infect the murine fibroblast cell line NIH-3T3 by standard methods. The cells were then visualized 48
5 hours after infection after staining for the LacZ product with X-gal immunohistochemistry.

Functional validation of adenoviral shuttle plasmids containing retroviral packaging functions showed that 293 cells were transduced with indicated plasmids by CaPO_4 and
10 supernatants used to infect target NIH-3T3 cells with X-gal staining at 48 h for the product of the LacZ gene. Transfections were with: a) pPAM3 and pLNCLZ; b) pPAM3; c) pLNCLZ; and d) pCAAmpg and pLNCLZ. The transfection with pPAM3 and pLNCLZ was positive. The transfection with pPAM3 and pLNCLZ was
15 negative. The transfection with pCAAmpg and pLNCLZ was positive.

Co-transfection of the control plasmids pPAM3 and pLNCRZ yielded retroviral transducing particles, as indicated by the presence of LacZ positive NIH-3T3 cells. In contrast,
20 transfection with either of these plasmids alone did not yield transducing retroviral particles. Next, co-transduction of the adenoviral shuttle vector encoding the retroviral packaging functions (pCAAmpg) with the retroviral vector plasmid pLNCLZ was then carried out. As for the co-transfection with both of the
25 control plasmids (pPAM3 and pLNCLZ), LacZ transducing retroviral particles were derived in this analysis. Thus, retroviral packaging functions are exploitable for retroviral particle derivation in the context of an adenoviral shuttle plasmid.

Studies were directed at determining whether
30 retroviral vector sequences could be rescued from an adenoviral shuttle plasmid. For this analysis, retrovirus particles were derived and transducing particles were analyzed as described above. The packaging plasmid employed for this analysis was pPAM3. It was utilized to rescue retroviral particles either from a
35 conventional retroviral vector plasmid, pLNCLZ, containing a LacZ gene flanked by retroviral LTRs, or from an adenoviral shuttle plasmid containing the same LTR-neo-CMV-LacZ-LTR segment (pAE1LNCMV-LacZ). As before, co-transfection of 293 with pPAM3

and pLNCLZ generated LacZ transducing retroviral particles, as indicated by X-gal staining of NIH-3T3 indicator cells. Additionally, neither plasmid alone possessed this capacity. Importantly, co-transfection of the adenoviral shuttle plasmid containing the retroviral vector sequence, pΔE1LNCMVlacZ, with the control retroviral packaging plasmid, pPAM3, also could be shown to generate LacZ transducing retroviral particles.

Functional validation of adenoviral shuttle plasmids containing retroviral vector functions was performed. For this analysis, 293 cells were transfected with indicated plasmids by CaPO₄ and supernatants used to infect target NIH-3T3 cells with X-gal staining at 48 h for the product of the LacZ gene. Transfections were with: a) pPAM3 and pLNCLZ; b) pPAM3; c) pLNCLZ; and d) pPAM3 and pΔE1LNCMVlacZ. The transfections were with pPAM3 and pLNCLZ was positive; the transfection with pPAM3 was negative; the transfection with pLNCLZ was negative; and the transfection with pPAM3 and pΔE1LNCMVlacZ was positive. Thus, retroviral vectors can be rescued from adenoviral shuttle plasmids for derivation of transducing particles.

These studies have thus independently established that retroviral packaging and vector functions can operate in the context of adenoviral shuttle plasmids to allow the generation of in vivo retroviral particles. It was important to demonstrate that these functions, when both in an adenoviral shuttle plasmid context, could also function to yield retroviral particles. For this analysis, the ability of retroviral packaging functions were evaluated in an adenoviral shuttle vector, pCAAmpg, to rescue retroviral vector functions in the adenoviral shuttle vector plasmid, pΔE1LNCMVlacZ. Control experiments with pPAM3 and pLNCLZ established the ability to derive particles in this assay. In addition, control transfection with pCAAmpg or pΔE1LNCMVlacZ also failed to yield particles independently. Co-transfection of these two plasmids, however, yielded LacZ transducing retroviral particles, as was noted in the positive control study.

The functional validation of adenoviral shuttle plasmids containing retroviral vector functions was performed. Transfection and supernatant assay was as described above. Transfections were with: a) pPAM3 and pLNCLZ; b) pCAAmpg; c)

pΔE1LNCMVlacZ; and d) pCAAmpg and pΔE1LNCMVlacZ. Transfection with pPAM3 and pLNCLZ were positive; the transfection with pCAAmpg was negative; the transfection with pΔE1LNCMVlacZ was negative; and the transfection with
5 pCAAmpg and pΔE1LNCMVlacZ was positive. Thus, this experiment confirms the generation of retroviral particles from adenoviral shuttle plasmids containing the minimum requisite retrovirus functions. This finding thus establishes the rationale to derive adenoviral vectors constructed on this basis.

10 Based on these results, adenoviral vectors were constructed encoding retroviral packaging functions or retroviral vector functions. These vectors were generated by standard methods via co-transfection of the indicated shuttle plasmids with the adenoviral packaging plasmid pJM17 as previously described.
15 Isolated plaques were then expanded, confirmed for identity by polymerase chain reaction (PCR), and plaque purified by three serial passages. After expansion, the identity of the vectors was confirmed by restrictive endonuclease digestion and PCR analysis of heterologous DNA segments of the E1A region at the adenoviral
20 genome. An example of this conformation is shown in Figure 4. These vectors are all E1A/B-deleted, replication-incompetent adenoviral vectors. These vectors were characterized *in vitro* for the functional utility of their retroviral packaging and vector functions as done for the corresponding shuttle plasmids. The
25 demonstration of the functional utility of these retroviral segments in the context of adenoviral vector allows execution of *in vivo* studies.

Based on these concepts, the present invention discloses a strategy in which adenoviral vectors are employed to
30 deliver growth factors to the relevant target parenchyma to induce proliferation. This maneuver can be employed in conjunction with *in situ* generation of retroviral vector via adenoviral-mediated gene delivery of retroviral vector and/or packaging functions. In this method, adenoviruses achieve high
35 efficiencies of *in vivo* gene delivery to target parenchyma of relevant growth factor genes. The high efficiency of delivery at relevant sites allows high local concentrations of the growth

factors to be achieved, with enhanced induction of target cell proliferation.

The adenoviral/retroviral chimeric vectors has been configured and its function validated. The recombinant
5 adenovirus containing the retroviral vector sequences, AdLNCMV_{LacZ}, has been constructed and functionally validated. A strategy was derived to achieve high, transient transfection of a non-293 cell line with retroviral packaging functions to determine whether retroviral vector sequences could be rescued from the
10 context of an adenoviral genome. For this requirement, the adenovirus-polylysine vector (AdpL) was employed. For this study, HeLa cells were transfected with AdpL complexes containing the plasmid pPAM3 to provide expression of retroviral packaging functions, and then infected with AdLNCMV_{LacZ}.
15 Control experiments demonstrated that co-transduction of HeLa with pPAM3 and PLNCLZ via AdpL resulted in the production of retroviral particles. In contrast, AdpL-transfection of the plasmid PLNCLZ only did not. When AdpL transfection with pPAM3 was followed by infection with AdLNCMV_{LacZ}, LacZ transducing
20 retroviral particles could be obtained. Of note, when HeLa cells were not pre-treated with AdpL/pPAM3, no such retroviral particles could be obtained. Thus, "carry-over" of the LacZ encoding adenovirus from the producer cells to the target cells did not explain this result. Thus, retroviral vector sequences can be
25 rescued from adenoviral vectors with the successful derivation of transducing retroviral particles.

Functional validation of AdLNCMV_{LacZ} was performed. For this analysis, HeLa cells were transfected via the AdpL method with retroviral packaging and/or vector plasmids. In some
30 instances cells were then infected with AdLNCMV_{LacZ}. Supernatants was then harvested and analyzed for LacZ transducing retroviral particles, as before. Transduction/infection conditions were: a) 'AdpL transfection with pPAM3 and PLNCLZ, b) AdpL transfection with PLNCLZ, c) AdpL transfection with
35 pPAM3 followed by infection with AdLNCMV_{LacZ}, d) Ad infection with AdLNCMV_{LacZ} only. Transduction/infection with AdpL transfection with pPAM3 and PLNCLZ was positive; AdpL transfection with PLNCLZ was negative; AdpL transfection with

pPAM3 followed by infection with AdLNCMVlacZ was positive; and Ad infection with AdLNCMVlacZ only was negative. All vectors used for these studies are Δ 1 A/B-deleted, replication-incompetent adenoviral vectors.

5

EXAMPLE 8

Patterns of gene expression in retroviral producer cells induced via adenoviral vector-mediated delivery

10 The basis of this strategy is efficient expression in target cells of retroviral packaging functions to allow rescue of retroviral vector sequences from the adenovirus vector vehicles. The patterns of gene expression of the retroviral packaging functions *gag/pol/env* were evaluated in various "conventional" 15 packaging systems, and compared to the pattern achieved by the adenoviral vector AdCMVampg, which also encodes these functions. In this regard, the packaging cell line GP+Am12 has been stably transduced to express amphotrophic retroviral functions and has been validated as an efficient vehicle for 20 packaging of retroviral vectors. In addition, transient transfection of the human embryonic kidney cell 293 via CaPO_4 microcrystalline particles with the *kat* packaging plasmids pKat2ampac and pLNCLZ has been shown to efficiently package co-transduced retroviral vector plasmids. These two cellular 25 systems were compared to HeLa cells transduced with the adenoviral vector AdCMVampg, with analysis of the magnitude and pattern of packaging functions achieved.

 For this analysis, the packaging cell line GP+Am12, 293 cells transduced via CaPO_4 with the plasmid pKat2ampac, and 30 HeLa cells infected with adenoviral vector AdCMVampg are subject to Northern blot analyses at various time points after induction. Comparable amounts of extracted total cellular RNA are transferred on nitrocellulose membranes and the resulting blots probed with ^{32}P -labeled oligonucleotides corresponding to the 35 retrovirus *gag*, *pol*, or *env* genes. The resulting blots provide a comparison of the magnitude and pattern of retroviral packaging gene functions achieved via adenoviral delivery compared to levels achieved via conventional packaging technologies. This data

allows one to optimize retroviral vector production from transient transfection of target cells via adenoviral vehicles.

EXAMPLE 9

5

Production of retroviral vectors via transient producer cells induced with adenoviral vector-mediated gene transfer

After establishing that an appropriate level and pattern of retroviral packaging functions may derive from an
10 adenoviral vector encoding the retroviral genes *gag/pol/env*, the production of transducing retroviral particles was accomplished. Comparison is made to "conventional" retroviral packaging systems including stable retroviral producer cell lines established by transduction of the amphotropic retroviral producer line
15 GP+Am12 with the plasmid pLNCLZ. This line stably produces retroviral particles encoding LacZ/neomycin. In addition, retroviral vectors were generated via transient co-transfection of 293 cells with CaPO₄ procedures with the amphotropic retroviral packaging plasmid pPAM3 in combination with the retroviral
20 vector plasmid pLNCLZ. For comparison, HeLa cells were co-transduced with normalized amounts of adenoviral vectors encoding retroviral packaging functions (AdCMVmpg) or retroviral vector functions (AdLNCMVlacZ).

At 48 h post-induction, supernatants were harvested
25 from target cells and analyzed for content of produced retroviral particles. A number of analyses were utilized to determine the titer and function of produced retroviral vectors. The magnitude of produced particles was directly determined by Northern blot for analysis of supernatants with probe via a cDNA for the
30 retroviral vector sequences. Serial dilutions of each supernatant were compared to standards containing known amounts of the retroviral vector plasmid. This assay thus yields information as to the level of retroviral vector sequences packaged into produced retroviral particles with each packaging system. In addition, the
35 titer of the produced retrovirus vector were directly determined by two methods. First, supernatants were delivered to the indicator cell line NIH-3T3 with infection by standard methods. After 48 h, these cells were stained for the product of the LacZ

gene with FDG and analyzed by FACS for transduction frequency. In addition, similarly infected NIH-3T3 cells were subject to stable selection in the presence of the neomycin analogue G418. After 21 days, the surviving colonies were stained by crystal violet and scored. In addition, some of the colonies were expanded and subject to analysis of the state of the retroviral vector DNA segments in the context of the host genome. Restriction analysis confirmed whether the DNA has integrated or is present as a episome.

These studies thus validate that transient retroviral producer cell lines can be derived with adenoviral vector-mediated delivery of retroviral packaging and vector functions. Further, transduction-competent retroviral particles can be generated, capable of achieving long term gene expression in target cells based on integration of transgene containing proviral sequences. In addition, a direct comparison of the number of functional transducing retroviral vector particles obtainable via adenoviral vector mediated-induction of a retroviral packaging line can be made in relation to standard methods.

EXAMPLE 10

Parameters for optimal production of retroviral particles via the adenoviral/retroviral chimeric system

Parameters which affect retroviral production from packaging cells include host cell factors, as well as the levels of retroviral packaging/vector functions achievable. In this regard, levels of adenoviral vector-mediated heterologous gene expression are generally a linear function of input particle number. This relationship holds until adenoviral vector-related toxicity attenuates heterologous gene produced by transduced cells. The determinants of optimized retroviral production via the adenoviral/retroviral chimeric system are shown. HeLa cells were co-transduced with equimolar amounts of the adenoviral vectors encoding retroviral packaging functions (AdCMVAmpeg) and retroviral vector functions (AdLNCMVLaclZ). As before, supernatants were harvested and analyzed for retroviral particle production. The amount of input adenoviral vector can be varied

to determine its relationship to retroviral vector output. Thus, HeLa cells were infected with adenoviral vectors at multiplicities of infection of 1, 10, 100, 500, and 1,000 particles/cell. Adenovirus-mediated cytotoxicity in retroviral producer cells (HeLa) was directly determined employing the MTT assay of cellular proliferation. Based on this analysis, the relationship between input adenoviral vector and output retroviral vector as may be dictated by limiting toxicities and/or linearity of response was determined.

Another variable which may affect net output of viral particles is the ratio of retroviral packaging functions and retroviral vector sequences realized in the retroviral producer cell. This is accomplished empirically in the context of stable retroviral producer lines by determining the producer cell lines with the highest retroviral titer. The ability to independently modulate both components of the system allows determination of the optimal ratio of packaging and vector functions to allow retroviral vector production. HeLa cells were co-infected with the adenoviral vector encoding retroviral packaging functions (AdCMVampg) and the adenoviral vector encoding retroviral vector functions (AdLNCMVlacZ) with analysis of product retroviral particle. Linear ratios of the two particles (1:1, 1:2, 1:4, etc.) were delivered with final analysis for transducing retroviral particles. These studies allowed a determination of the precise ratios of retroviral functions most consistent with vector production in the context of the adenoviral/retroviral chimeric system.

EXAMPLE 11

30

Retroviral production via the adenoviral/retroviral chimeric system in murine cell lines

Methods to achieve cell-specific delivery with long term gene expression were examined with respect to airway epithelium (lung), vascular endothelium (heart), and liver (metabolic blood, i.e., hemophilia). The capacity of murine hepatocytes to function as retroviral producer cells was determined. For this analysis, direct comparison was made

between stable retroviral vector producer cells, 293 cells transiently transfected with retroviral packaging and vector plasmids, and both HeLa cells and the murine hepatoma cells infected with equivalent amounts of the adenovirus/retrovirus vectors with packaging and vector functions. Derived retroviral particles were analyzed. This analysis shows a direct determination as to the level at which murine cells from a relevant parenchymal organ target can function as transient retroviral producer cells.

Murine cells can be infected by ecotropic and amphotropic retroviral vectors. Retroviral vectors derived from either ecotropic or amphotropic *env* glycoproteins were of comparable efficacy. It has not been established, however, whether murine cells function differentially with respect to production of ecotropic versus amphotropic retroviral vectors. As the methods of the present invention involve local production of retroviruses *in situ* in the context of murine parenchymal cells, the ability of the murine hepatocyte line to produce ecotropic versus amphotropic retroviral vectors via the adenoviral/retroviral chimeric strategy was shown. To achieve this, a flexible approach was developed to alter the envelope glycoprotein in retroviral particles. An adenoviral vector encoding the retroviral packaging functions *gag* and *pol* (AdCMVGP) was developed. In addition, distinct adenoviral vectors encoding either the ecotropic or amphotropic *env* glycoprotein were developed. It is thus feasible to derive amphotropic retroviral particles by co-transductions of target cells with AdLNCMV_{LacZ} and the adenoviral vectors encoding *gag/pol* (AdCMVGP) and amphotropic *env* (AdCMVEnv^a) or to derive ecotropic retroviral particle by co-transfection of target cells with AdLNCMV_{LacZ} and the adenoviral vectors encoding *gag/pol* (AdCMVGP) and ecotropic *env* (AdCMVEnv^e) via the adenovirus/retrovirus chimeric system of the present invention.

For this analysis, the murine hepatocyte cell line was subjected to infection with the relevant combination of adenoviral vectors, inducing them to function either as transient producers of recombinant ecotropic or amphotropic retroviral vectors. The derived vectors were then analyzed by titer against NIH-3T3, with

scoring via LacZ gene expression and neo selectable clones. This analysis determines any cellular constraints with respect to murine cells functioning as retroviral producer cells. It will also directly determine specific production issues relevant to production of ecotropic versus amphotropic retroviral vectors.

EXAMPLE 12

Retroviral vector production via the adenoviral/retroviral chimeric system in murine primary cells

Murine primary cultures of hepatocytes were established employing standard methods of collagenase digestion and purification. These target cells were evaluated for a variety of parameters relevant to retroviral production including: 1) the pattern and magnitude of retrovirus packaging function genes induced by the adenoviral/retroviral chimeric system; 2) the magnitude of production of retroviral vectors induced by the adenoviral/retroviral chimeric system; 3) the optimization of parameters for production of retroviral vectors induced by the adenoviral/retroviral vector chimeric system; 4) the differential production of ecotropic and amphotropic retroviral vectors via the adenoviral/retroviral vector chimeric system. These studies use as endpoint assays the production of transducing retroviral particles as assayed by LacZ histochemical positivity and neomycin resistance. This allows the determination of the optimal parameters relevant to retroviral vector production in the context of an appropriate target cell will the highest level of analogy to the *in vivo* context.

EXAMPLE 13

Retroviral receptor induction as a means to augment retroviral transduction via the adenoviral/retroviral chimeric system

In situ generation of retroviral vectors that transduce neighboring parenchymal cells allowS for their stable genetic modification. Once a high local concentration of retroviral vectors has been generated via the adenoviral/retroviral chimeric approach, other factors may have a bearing on the actual transduction of surrounding target cells. In this regard, for stable

genetic modification of target cells to occur via retroviral vectors, the transduced cells must be in a proliferative state. The local concentration of receptor for the produced retrovirus may also be a factor dictating the efficacy at which neighbor cells are transduced. The receptor levels for ecotropic or amphotropic viruses can be a limiting factor dictating overall susceptibility of a target cell to infection with this vector. In addition, heterologous expression of the cognate retroviral receptor can: 1) increase the susceptibility of target cells by increasing the number of effective transducing events based on receptor-*env* interactions and/or 2) render previously resistant cells sensitive to retroviral infection by providing the previously deficient function allowing receptor-*env* interaction. Modulation of retrovirus receptor population may be an important determinant of transductional efficacy with these vectors.

cDNA clones were obtained for the receptors corresponding to the envelope glycoprotein of ecotropic retrovirus (eco-R) and for the envelope glycoprotein of amphotropic retrovirus (ampho-R). These have been configured into adenoviral vectors, whereby the retroviral receptor is expressed via the CMV intermediate early promoter/enhancer in the context of an E1A/B deleted, replication-incompetent adenoviral vector. These vectors are employed to infect primary murine hepatocytes by standard procedure. These target hepatocytes are then subject to infection with ecotropic and amphotropic retroviral vectors encoding the LacZ/neo cassette. Comparison is made to murine primary hepatocytes which have not been transduced with retroviral encoded cDNAs. As before, indicator cells are scored for retroviral induction of LacZ histochemical positivity and neomycin resistance. Additional parameters which may be evaluated include the effect of target retroviral receptor number on retroviral vector sensitivity. In addition, the differential capacities of ecoR and amphoR induction can be compared. These studies determine if retroviral receptor induction can enhance retroviral transduction of relevant target cells. This strategy exploits the efficient *in vivo* gene transfer characteristics of adenoviral vectors to achieve the retroviral receptor induction *in situ*. Thus, adenoviral vectors are used to generate retroviral

producer cells at target organ sites to infect neighboring cells via elaborated retroviral particles. The enhancement of this process via induction of retroviral receptors at the neighboring cells also exploits adenoviral vector mediated gene delivery.

5

EXAMPLE 14

Production of VSV-G pseudotyped retroviral vectors via the adenoviral/retroviral chimeric system

Pseudotyped retroviruses have been employed to overcome target cell retroviral receptor limitations in the context of achieving efficient gene transfer via retroviral vectors. In this regard, chimeric retroviral particles may be generated which contain alternate *env* glycoproteins, most generally derived from vesicular stomatitis virus G-glycoprotein (VSV-G). These chimeric retroviral particles may then infect cells by virtue of the VSV-G glycoprotein's interaction with target cell receptors. This means of achieving alternate cellular entry may thus obviate the lack of target receptors for amphotropic or ecotropic *env* glycoproteins. This strategy has been employed both to infect retroviral resistant cells, as well as a means to increasing transduction efficiency. In addition, these pseudotyped vectors may possess a higher level of stability *in vivo*, potentially allowing for higher levels of *in situ* transduction in the *in vivo* delivery context. These VSV-G pseudotyped retroviruses are generated by coordinate expression of amphotropic or ecotropic *gag/pol* with the VSV-G glycoprotein. The assembling retroviral particle incorporates VSV-G instead of the amphotropic or ecotropic *env* counterpart. One means to achieve this end has been co-transduction of cells with plasmids encoding retroviral *gag/pol* and VSV-G plus retroviral vector plasmids. Transduced cells are rendered as transient producers of retroviral pseudotypes. Whereas this method may produce the desired pseudotyped retroviral particles, toxicity associated with the VSV-G glycoprotein is manifested in producer cells which eventuates in attenuated production and thus reduced overall titers. Packaging cell line strategies have been developed exploiting regulatable expression units. Stable cells are derived which constitutively express retroviral *gag/pol* and also contain VSV-G in an inducible expression cassette. Following transduction

of these cells with a retroviral vector plasmid, VSV-G expression was induced to allow derivation of pseudotyped vectors. This maneuver allows the stable maintenance of cell lines capable of generating pseudotyped particles, as well as allowing an augmented level of vector production.

An adenoviral/retroviral chimeric system was employed to render target cells into transient producers of VSV-G pseudotypes. This maneuver may have advantages in infecting neighbor cells *in vivo*. Such an augmented transduction efficiency may reflect improved target cell infection efficiencies. Alternatively, such an observation might reflect greater *in vivo* stability of the pseudotyped retroviral particles. For this analysis, target cells were employed as model systems of increasing stridency. Thus, HeLa cells, the murine hepatocyte cell line BNL CL.2, and finally murine primary liver cells were induced as transient VSV-G pseudotyped retroviral producers by the adenoviral/retroviral chimeric system.

For generation of pseudotyped retroviruses, cells were co-infected with an adenoviral vector containing retroviral *gag/pol*, CAdCMVGP, an adenovirus encoding retroviral vector sequences (AdLNCMVLaZ), plus an adenoviral vector encoding the VSV-G glycoprotein. This latter vector was obtained from L. Prevec (McMaster University, Ontario, Canada). This is an E1A/B deleted replication-incompetent adenoviral vector capable of expressing VSV-G at high levels of various eucaryotic target cells. These cells were also induced for generation of ecotropic and amphotropic retroviral vectors via the adenoviral/retroviral chimeric system employing AdCMVEnve and AdCMVEnva, respectively. After infection, cell supernatants were harvested and used to infect target indicated cells. Initially, NIH 3T3 cells were infected with scoring for LacZ induction and the generation of neomycin selectable clones. This analysis gives an index of the relative titers which may be generated for VSV-G pseudotypes by this method compared to the amphotropic and ecotropic retroviral vectors. In addition, the supernatants were employed to infect murine hepatocyte primary cells with LacZ scoring. This analysis determines whether the pseudotyping maneuver allows a greater infectivity of parenchymal targets based on VSV-G target cell

receptor interactions. Correlative studies determined if the VSV-G transduction event was associated with vector proviral integration. This is important as VSV-G has been associated with "pseudo-transduction" whereby heterologous gene product transfer occurs within actual stable genetic modification of the target cells. Additionally, whether induced expression of the VSV-G glycoprotein can further optimize vector production via the adenoviral/retroviral chimeric system was determined. Whether this inductibility allows higher titers VSV-G pseudotypes to the derived was evaluated. These studies thus allow determination of whether the adenoviral/retroviral chimeric system may function to yield VSV-G pseudotyped retroviral particles. Further, whether these particles possess an augmented transduction capacity for relevant parenchymal targets *in vitro* was determined.

15

EXAMPLE 15

Adeno/retro chimeric vectors to modify parenchymal cells *in vivo*

The present invention establishes methods to use adenoviral vectors to induce target cells to function as retroviral producer cells. Further, these methods can be optimized to target tissues relevant to models of heart, lung, and blood disease. Using this strategy *in vivo*, one may achieve long term stable integration at target parenchymal sites. *In vivo* studies were undertaken in two delivery contexts: 1) hepatocyte transduction via systemic vascular delivery and 2) airway epithelial transduction via luminal airway delivery. These routing schemas represent delivery routes whereby high efficiency *in vivo* transduction of relevant parenchymal can be achieved. Thus, *in vivo* retroviral delivery efficacy of gene functions is not a confounding variable. Adenoviral vectors were employed to induce target cells to function as retroviral producers. The elaborated retroviruses then function to transduce surrounding parenchymal cells.

20
25
30

EXAMPLE 16

In situ retroviral infection of target cells after *in vivo* induction of retroviral production at parenchymal sites

The degree and extent to which retroviruses were elaborated *in vivo* was determined. As the produced virions can

not be feasibly retrieved after generation *in situ*, this analysis determines this result indirectly, by evaluating the degree to which neighbor cells have been stably transduced via retroviral vectors. For these studies, mice were challenged with a combination of the adenoviral vector encoding retroviral packaging functions and the adenoviral vector encoding retroviral vector sequences to achieve either airway epithelial or hepatocyte delivery. The expression of the packaging functions and the expressed product of the derived retroviral vector (LacZ/neo) were independently confirmed at target organs via quantitative polymerase chain reaction of mRNA transcripts (*gag/pol/env*) and/or DNA copy number (LTR/LacZ/neo). In addition, target cells specifically producing these retroviral components were determined by *in situ* hybridization of tissue sections deriving from the lung and liver. These studies confirm that adenoviral vector delivery can achieve expression of retroviral packaging functions *in vivo* at target organ sites. Further, specific cells subset potentially functioning as retroviral producer cells can be identified.

Determination of the degree to which integration may be occurring by target cell transduction with elaborated retroviruses is carried out by analysis of the state of proviral DNA within the context of host organ genomic DNA. After local elaboration of retroviral particles, transduction of surrounding cells should generate integrated copies of the retroviral proviral genome. Total cellular DNA was extracted after induction with the adenoviral/retroviral chimeric system and subjected to analysis for the state of proviral DNA. Initially, tissue material undergoes Hirt DNA extraction. Derived DNA was then analyzed by Southern Blot for the presence and state of adenovirus-derived sequence. The majority of the retroviral vector DNA should be detected as non-integrated episomes within the Hirt fraction. This would be the case for AdCMVampg genomes, as well as least a portion of the AdLNCMVlacZ genomes. Next, high molecular weight DNA were analyzed in a similar manner. The genome of the two adenoviral vectors should not be detected in the HMW DNA fraction, as they are episomal, and migrate in the context of Hirt extractable DNA. In contrast, if integration occurs to any extent,

the proviral component of AdLNCMV_{LacZ} are detected in the high molecular weight fraction by Southern blot analysis. This was confirmed by restriction endonuclease digestion in combination with Southern blot of both Hirt fractions and HMW fractions of DNA derived from these two target organ sites. Comparison were made to controls whereby delivery of only retroviral packaging functions or retroviral vector functions via adenovirus was carried out. This analysis functions as a high sensitivity "screen" to determine whether an integration event has occurred as a result of *in situ* retroviral vector transduction via the adenoviral/retroviral chimeric system.

An additional assay of *in situ* retroviral infection is longevity of vector proviral DNA or DNA-encoded sequences at the target site. Stable, long term gene expression derives from *in situ* retroviral infection of these target organs. In the first instance, integration of the vector proviral DNA at target organ parenchymal cells would be manifested as long term persistence of this DNA sequence in the context of the host genome DNA. Thus, the temporal pattern of the vector proviral DNA was examined. In this regard, animals were challenged, as before, with the combination of AdCMV_{Amp} and AdLNCMV_{LacZ} for lung and liver transduction. At specific time intervals post-treatment, the indicated organs are harvested and subject to both Hirt DNA extractions and HMW DNA extractions. Analysis of the amount of both adenoviral vector genomic DNA and retroviral proviral DNA was undertaken by employing quantitative PCR to determine absolute amounts of the integrated retroviral vector DNA within host HMW genomic DNA at each time point. A temporal profile indicating persistence proviral vector sequences within the HMW fraction indicates the degree to which stable integration has occurred. An additional index of persistence, based on vector proviral integration, was carried out employing histochemical reporters. Both LacZ and GFP were employed as reporters whose expression can be detected by histochemical analysis of appropriate processed tissue section. The transient expression profile of these reporter genes at the airway epithelium and liver after adenoviral vector transduction has been well documented. Thus, the temporal pattern of the reporter gene should be indicative of *in*

situ retroviral generation with consequent integration of vector proviral DNA. Animals were challenged with AdCMV Ampg and AdLNCMV LacZ, or AdLNCMV GFP, for liver and lung transduction. At various time points post-treatment, relevant organs were harvested with histochemical analysis for the products of the encoded LacZ and GFP genes. This analysis was complemented by *in situ* hybridization of tissue sections for the mRNA production of these reporter genes to provide an additional quantitative index. In this analysis, a differential in the pattern of persistence would be anticipated in the *in situ* retroviral vector group compared to reporter encoding adenoviruses alone.

EXAMPLE 17

Enhancement of *in situ* retroviral infection via *in vivo* adenoviral delivery of retroviral packaging and vector functions

The ability of locally elaborated retroviral vectors to stably transduce parenchymal target cells is impacted by local cellular factors. These factors include the proliferative state of the target cell as well as the number of receptors for the locally produced retroviral vectors. To modulate target cell proliferation, a strategy based on growth factor induction was used. A strategy of growth factor induction for enhancement of target cell proliferation was used; however, adenoviral vectors were employed to achieve efficient *in vivo* delivery to the lung and liver of a gene construct encoding the growth factors KGF and hepatocyte growth factor (HGF). High local concentrations of these growth factors achieved by this method provide an optimized induction of proliferation of parenchymal cells at these organ sites and this proliferation induction allows enhanced transduction of target cells by locally elaborated retroviral vectors.

Animals were initially challenged by delivery of adenoviral vectors encoding KGF or HGF to the lung or liver. After establishment of the temporal profile for optimal induction of proliferation, animals were challenged with the adenoviral/retroviral chimeric vectors AdCMV Ampg and AdLNCMV LacZ for *in situ* retroviral generation. These animals then underwent analysis to determine the degree of integrated

proviral vector sequences. These studies include PCR quantification of integrated proviral sequences within the HMW DNA fraction of lung and liver, as well as *in situ* hybridization for determination of the number of stably transduced cells.

5 Correlative studies determine the degree to which induced proliferation was a factor predicting successful *in situ* retroviral transduction. The aggregate of these studies allows the determination of the degree to which induced proliferation via adenoviral vector-mediated delivery of growth factor genes can

10 favorably influence the ability of *in situ* generated retroviral vectors to achieve stable transduction of parenchymal targets.

EXAMPLE 18

15 Adenoviral vectors can induce target cells to function as retroviral producers

Target cells were infected with a combination of the adenoviral vectors, AdCMVAmpg and AdLNCMVGFP, or with AdLNCMVGFP only. Target cells were either the monkey vero cell

20 line WI62, the murine fibroblast cell line NIH-3T3, the human bladder cancer cell line EJ, or the human ovarian cancer cell line SKOV3_{ip1} (data not shown). Cells were infected with the appropriate adenoviral vectors for 3 h and then washed to remove any free adenovirus. These cells were maintained in tissue

25 culture for various time periods and then analyzed for the expression of the green fluorescent protein (GFP) reporter gene by fluorescence-activated cell sorting (FACS) or by fluorescent microscopy.

Analysis of adenoviral vector infected cells at day 2

30 post-infection showed that both groups, the control and the putative retroviral producers, demonstrated a high frequency of expression of the GFP reporter gene (Figure 5). This is consistent with a high initial frequency of AdLNCMVGFP infection having occurred in both groups, with subsequent GFP gene expression

35 occurring in both groups as well. A subset of each group was passaged every 8 days and then analyzed at day 30 and day 60. FACS analysis of the cell group that had been exposed to both adenoviral vectors (AdCMVAmpg and AdLNCMVGFP) showed a

substantially higher number of GFP-positive cells compared with the cells that had received only AdLNCMVGFP (Figure 6A). The GFP-positive cells from the group infected with both viruses were present in clustered out-growths suggesting local retroviral spreading and/or clonal origin (Figure 5). This is in marked contrast to the cells infected with AdLNCMVGFP alone, which had lost GFP expression, consistent with the known transient expression of genes delivered by the standard adenovirus approach (Figures 5 and 6A). Proviral integration was confirmed by the demonstration of retroviral sequences in high-molecular-weight cellular DNA (Figure 6B).

EXAMPLE 19

15 Production of transducing retroviral particles

NIH-3T3 or WI62 cells were infected with either a combination of AdCMVAmpg and AdLNCMVGFP, or AdLNCMVGFP only, then subsequently washed as before. The supernatants were harvested at 48 h postinfection and then used to infect NIH-3T3 cells to determine retroviral titers. The supernatant-infected cells were maintained in culture for 20 days and analyzed for GFP expression. The supernatant derived from the AdLNCMVGFP-virus infected cells was not capable of inducing long-term GFP expression in target cells (Figure 7). In contrast, cells infected with AdCMVAmpg plus AdLNCMVGFP supernatant demonstrated a high rate of GFP expression at day 20. This study confirms that GFP induction resulted from infection with retroviruses derived from the original adenovirus-infected target cells. These long-term GFP expression studies were designed to distinguish carryover adenoviral transient gene expression (<2 weeks) from stable transduction mediated by retrovirus production. The results suggested that transducing retroviral particles had indeed been generated by adenoviral-vector delivered genes in target cells.

35 To determine whether this methodology was associated with significant production of replication-competent retrovirus (RCR), RCR generation derived via plasmid-based transfection methods was compared to the use of the

adenoviral/retroviral chimeric vector. HeLa cells were thus transfected with either pPAM3 plus pLNCLZ, or infected with AdCMVAmpg or AdLNCMVGFP, or AdCMVAmpg plus AdLNCMVGFP. These supernatants were then analyzed for the presence of replication-competent retroviruses. No replication-competent retroviruses were detected with the adenoviral/retroviral chimera (data not shown). Thus, the generation of replication-competent retroviruses by this method does not appear to be in excess of conventional methods.

10

EXAMPLE 20

In vivo gene transfer with stable integration

Having established these key concepts, this methodology was employed to accomplish *in vivo* gene transfer with stable integration. This was carried out to determine the overall utility of this approach in the most stringent delivery context. For this analysis, a murine model of human carcinoma of the ovary was employed. Athymic nude mice were thus xenografted orthotopically with the human carcinoma cell line SKOV3_{i.p1}. After establishment of peritoneal tumor plaques, animals were then vector challenged via the intraperitoneal (i.p.) route. Groups of animals received either the adenoviral/retroviral vector chimeric or this vector plus the adenoviral/retroviral packaging chimera. In the former instance, the employed vector, AdLNCMVGFP, contained retroviral vector sequences with the GFP reporter gene. In the latter instance, the adenoviral vectors AdCMVAmpg, derived from pCAAmpg, contained the functionally validated retroviral packaging functions. In the one virus group, the adenoviral vector-mediated delivery of the GFP expressing cassette should result in *in vivo* gene expression with a temporal profile of rapid extinction based on non-integrative heterologous gene transfer. In contrast, the two viruses were anticipated to achieve *in situ* induction of tumor cells to function as retroviral producer cells. The locally elaborated retroviral vectors would then be anticipated to achieve stable transduction of proliferative neighbor cells, in this instance, the SKOV3_{i.p1} carcinoma targets. Based upon these considerations, the two original groups would be anticipated to exhibit distinctly

different temporal profiles of expression of the GFP reporter gene based on their differential ability to achieve stable transduction. Animals treated with the adenoviral/retroviral vector chimera AdLNCMVGFp were analyzed by fluorescent microscopy for tumor cells exhibiting GFP expression at early and late points post-delivery. In this analysis, the group of animals receiving the single vector demonstrated rare single positive cell at late time points as shown in Figure 8. In contrast, the animals that received the combination of adenoviral/retroviral vector chimera plus the adenoviral/retroviral packaging chimera exhibited a distinctly different pattern at late time points. In this regard, the analysis of this group was noteworthy for the detection of increased numbers of positive cells which occurred in clusters. This finding was consistent with the concept that stable transduction of target cells had occurred with clonal expression.

EXAMPLE 21

In vivo efficacy of the adenoviral/retroviral chimera

The ovarian carcinoma cell line SKOV3_{ip1} was infected *in vitro* with either AdCMVAmplg plus AdLNCMVGFp, or AdLNCMVGFp alone. To confirm the *in vivo* generation of infected retroviral particles and infection of neighboring cells, infected cells were mixed with uninfected cells at a ratio of 25% adenoviral-vector infected cells with 75% untreated SKOV3_{ip1} cells and implanted subcutaneously in athymic nude mice to allow tumor formation. Twenty days after implantation, both animal groups had palpable tumors that were harvested for analysis of GFP reporter gene persistence and expression. The group infected with AdLNCMVGFp only had rare, isolated fluorescent cells (Figure 9B). In contrast, the tumors derived from the two-virus group had large expansive clusters of GFP positive cells (Figure 9C). Counting of positive cells in multiple fields allowed an estimate of transduced cells such that the one-virus group had >80% GFP-positive cells. Thus, in this group, the number of positive cells was substantially greater than the proportion of adenovirally infected cells in the original implanted mixture. The extensive distribution of GFP-positive cells in the two-virus group suggested stable

genetic modification of neighboring cells via *in situ* retroviral vectors.

5 The potential to link *in vivo* adenoviral vector transduction to *in situ* retroviral producer generation was examined. Nude mice were orthotopically transplanted with the human ovarian cancer cell line SKOV3_{ip1}. Five days post-implantation, animals were treated intraperitoneally with either AdLNCMVGFP only, or AdLNCMVGFP plus AdCMVAmpg. 16 days post-adenovirus infection, the animals were sacrificed and tumors
10 analyzed. No GFP-positive cells could be detected in the one-virus group (Figure 9E). In contrast, islands of GFP-positive cells could readily be detected in the group that received both adenoviral vectors (Figure 9F). Again, analysis of multiple microscopic fields demonstrated an overall transduction rate of <1% for the one-virus
15 group and 10-15% for the two-virus group. The persistence of GFP expression *in vivo* in the group receiving the two adenoviral vectors, which allow full induction of retroviral packaging, is consistent with the *in vitro* findings whereby stable transduction had occurred based on secondarily elaborated retroviral vectors.

20

EXAMPLE 22

Summary

25 A novel vector approach has been developed to achieve efficient and stable genetic modification of target cells *in vivo*. This was accomplished by using the adenovirus as a delivery system for retroviral vector and packaging components and therefore inducing target cells to function as transient producers of retroviral vectors *in situ*. This strategy thus allowed
30 the generation of retroviral vector particles capable of infecting neighboring cells and accomplishing stable transduction. In this approach, two key factors allowed this level of stable transduction *in vivo*. First, the local production of retroviral vectors at the site of the target cells circumvented the deleterious effects of exposure
35 of the retroviral particles to humoral factors which would have resulted in their inactivation. Second, the efficient induction of retroviral producer cells *in situ* capitalized on the ability of adenoviral vectors to achieve effective *in vivo* delivery to target

cells. This strategy thus represents a novel conceptual approach whereby desirable aspects of component vector systems are combined to achieve a gene delivery goal.

5 Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

10 One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds
15 described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Curiel, D.
- (ii) TITLE OF INVENTION: Chimeric
5 Retrovirus/Adenovirus
System
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Benjamin A. Adler, Ph.D., J.D.
10 (B) STREET: 8011 Candle Ln.
(C) CITY: Houston
(D) STATE: TX
(E) ZIP: 77071
- (v) COMPUTER READABLE FORM:
15 (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: Apple Macintosh
(C) OPERATING SYSTEM: Macintosh
(D) SOFTWARE: Microsoft WORD 6.0
- (vi) CURRENT APPLICATION DATA:
20 (A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATE:
(A) APPLICATION NUMBER:
25 (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Benjamin A. Adler
(B) REGISTRATION NUMBER: 35,423
(C) REFERENCE/DOCKET NUMBER: D6015

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (713) 777-2321

(B) TELEFAX: (713) 777-6908

(C) TELEX:

5 (2) INFORMATION FOR SEQ ID NO: 1

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29bp

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single-stranded

10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

(A) DESCRIPTION: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTISENSE: no

15 (v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(vii) IMMEDIATE SOURCE:

(viii) POSITION IN GENOME:

(ix) FEATURE:

20 (x) PUBLICATION INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 1

GGGAAGCTTA TGGGCCAGAC TGTTACCAC 29

(3) INFORMATION FOR SEQ ID NO: 2

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 26

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single-stranded

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

(A) DESCRIPTION: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTISENSE: no

(v) FRAGMENT TYPE:

5 (vi) ORIGINAL SOURCE:

(vii) IMMEDIATE SOURCE:

(viii) POSITION IN GENOME:

(ix) FEATURE:

(x) PUBLICATION INFORMATION:

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 2

CAAGGCTTCC CAGGTCACGA TGTAGG 26

WHAT IS CLAIMED:

1. A chimeric adenoviral/retroviral vector, comprising:
at least one adenoviral vector containing retroviral sequences.

5

2. The vector of claim 1, wherein said chimeric
adenoviral/retroviral vector comprises:

(a) a replication-deficient adenoviral vector containing
retroviral vector functions; and

(b) at least one replication-deficient adenoviral vector
containing retroviral packaging functions.

3. The vector of claim 2, wherein said retroviral
vector functions comprise a heterologous gene flanked by
retroviral long terminal repeats.

4. The vector of claim 2, wherein said retroviral
packaging functions are selected from the group consisting of
gag, *pol* and *env*, or combinations thereof.

5. The vector of claim 4, wherein said *env* gene is a
vesicular stomatitis virus G-glycoprotein.

6. The vector of claim 1, wherein said heterologous
gene is selected from the group consisting of a gene encoding a
therapeutic protein, a selectable marker and a reporter gene.

7. A method of stably transducing target cells,
comprising the step of administering the chimeric
adenoviral/retroviral vector of claim 1 to an individual in need of
such treatment.

8. The method of claim 7, wherein said chimeric adenoviral/retroviral vector comprises:

(a) a replication-deficient adenoviral vector containing retroviral vector functions; and

5 (b) a replication-deficient adenoviral vector containing retroviral packaging functions.

9. The method of claim 8, wherein said retroviral
10 vector functions comprise a heterologous gene flanked by retroviral long terminal repeats.

10. The method of claim 8, wherein said retroviral
15 packaging functions are selected from the group consisting of *gag*, *pol* and *env*.

11. The method of claim 10, wherein said *env* gene is a
20 vesicular stomatitis virus G-glycoprotein.

12. The method of claim 9, wherein said
heterologous gene is selected from the group consisting of a gene
25 encoding a therapeutic protein, a selectable marker, a reporter gene.

13. The method of claim 7, wherein said replication-
30 deficient adenoviral vector containing retroviral vector functions;
and said replication-deficient adenoviral vector containing
retroviral packaging functions are co-transduced into a host cell,
wherein expression of the genes encoded by said adenovirus
shuttle vector results in the production of retrovirus particles
35 containing said therapeutic gene, wherein said retrovirus particles
infect neighboring cells, wherein said retrovirus particles stably
integrate said therapeutic gene into said host cells' genomic DNA.




FIGURE 1






FIGURE 2

3/9

- A. E1 substitution recombinant adenovirus encoding Moloney murine leukemia retrovirus vector components and gene interested expression cassette.



- B. E1 substitution recombinant adenoviruses expressing retroviral packaging components.



- C. Analysis of AdCMVAmpg viral genomic DNA. a) PCR confirmation results;
b) Restriction enzyme digestion analysis.





FIGURE 3




FIGURE 4





FIGURE 5

6/9

A.



B.






FIGURE 6

7/9

Supernatants from NIH3T3



Supernatants from W162



AdLNCMVGFP

AdLNCMVGFP
+
AdCMVAmpg





FIGURE 7






FIGURE 8




FIGURE 9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/21169

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 48/00; C12N 15/86

US CL :424/93.2, 93.6; 435/172.3, 320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.2, 93.6; 435/172.3, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog, Medline, Biosis, Biotech

Search terms: adenovirus, adenoviral vector, retrovirus, retroviral vector, chimeric, hybrid, gene therapy

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BACCHETTI et al. Inhibition of Cell Proliferation by an Adenovirus Vector Expressing the Human Wild Type p53 Protein. International Journal of Oncology. October 1993, Vol. 3, pages 781-788, especially page 781.	1-13
A	CULVER et al. Gene Therapy for Cancer. Trends in Genetics. May 1994, Vol. 10, No. 5, pages 174-178, especially pages 176-177.	1-13
A	BERKNER, K.L. Expression of Heterologous Sequences in Adenoviral Vectors. Current Topics in Microbiology and Immunology. 1992, Vol. 158, pages 39-66, especially pages 47-50.	1-13



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

13 JANUARY 1998

Date of mailing of the international search report

10 FEB 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID GUZO

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/21169

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SMITH, A.E. Viral Vectors in Gene Therpay. Annual Review of Microbiology. 1995, Vol. 49, pages 807-838, especially pages 816-821.	1-13

44